trending Market Intelligence /marketintelligence/en/news-insights/trending/ZiX4NVSuOKr7vw9nmbKdVQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption

Street Talk Podcast

Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4

Street Talk Podcast

Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief

Amid Q1 APAC Fintech Funding Slump, Payment Companies Drove Investments

Mérieux Equity invests in French pharmaceutical laboratory Addmedica

Mérieux Equity Partners SAS made an investment in French pharmaceutical laboratory Addmedica SAS through its Mérieux Participations 3 SLP fund.

The private equity firm became the reference shareholder of the company in partnership with founders François Anger and Bernard Dauvergne.

Addmedica develops and markets medicinal products and medical devices for rare diseases, including a benchmark treatment for inherited blood disorder sickle cell disease. The company will use the capital to expand its global footprint and product portfolio.

Duteil et Associés Law Firm and Advance Capital provided support to Mérieux Equity.